2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Vaccines, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Bleeding and Clotting, Platelet Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MPN, CML, Clinical Research, Clinical Trials, Study Population, Human, Adult, Animal Model
PAPER

1974 Safety and immunogenicity of a mutant calreticulin peptide vaccine in myelofibrosis

Cansu Cimen Bozkus, PhD, Anna Kaminska, MS2, Leandra Velazquez, MPH3, Kathryn Johnson, DNP4, Linda Lee, PhD5, Deniz Demircioglu, PhD6, Dan Hasson, PhD7, Michal Bar-Natan, MD8, Mansi Saxena, PhD9, John O. Mascarenhas, MD10, Camelia Iancu-Rubin, PhD11, Ronald Hoffman, MD12, Nina Bhardwaj, MD, PhD13, Marina Kremyanskaya, MD, PhD14
1 Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 Icahn School of Medicine at Mount Sinai, New York, New York, United States
3 Icahn School of Medicine at Mount Sinai, New York, New York, United States
4 Icahn School of Medicine at Mount Sinai, New York, New York, United States
5 Icahn School of Medicine at Mount Sinai, New York, New York, United States
6 Icahn School of Medicine at Mount Sinai, New York, New York, United States
7 Icahn School of Medicine at Mount Sinai, New York, New York, United States
8 NewYork-Presbyterian Weill Cornell Medical Center, New York, New York, United States
9 Icahn School of Medicine at Mount Sinai, New York, New York, United States
10 Icahn School of Medicine at Mount Sinai, New York, New York, United States
11 Icahn School of Medicine at Mount Sinai, New York, New York, United States
12 Icahn School of Medicine at Mount Sinai, New York, New York, United States
13 Icahn School of Medicine at Mount Sinai, New York, New York, United States
14 Icahn School of Medicine at Mount Sinai, New York, New York, United States

Introduction: Therapeutic cancer vaccines are emerging as a clinically impactful modality, yet vaccine-induced immunity in active disease, particularly in hematological malignancies, remains poorly understood. We designed a Phase I trial (NCT05025488) in patients (pts) with myeloproliferative neoplasms (MPNs) carrying calreticulin (CALR) mutations to evaluate an off-the-shelf peptide vaccine targeting mutant calreticulin (mutCALR), a shared immunogenic antigen and the second most common driver of MPN.

Methods: Pts were eligible if they had mutCALR-positive, previously treated high-risk essential thrombocythemia (ET) or low- or intermediate-1-risk myelofibrosis (MF) by DIPSS. A total of 10 vaccine doses comprised of 25mer peptides spanning the last 44 amino acids of the mutCALR C terminus were administered intramuscularly in combination with the adjuvants keyhole limpet hemocyanin (KLH, first dose only) and poly-ICLC in a prime-boost schedule for a total of 32 weeks. Pts with at least stable disease could continue into a maintenance phase, with 4 more vaccine doses administered through week 79. Primary objective of the study was evaluating the safety and tolerability of mutCALR vaccine. Key secondary objectives were assessing the immune response to the vaccine, changes in driver mutation burden and the response by IWG/ELN criteria.

Results: Seven pts were enrolled, including six with primary MF and one with post-ET MF. Overall, the study drug was safe and well tolerated. Grade 1-2 injection site reactions occurred in all pts. Other common adverse events (AEs) were headaches, myalgias, fevers and fatigue. No grade 3-4 AEs were reported. There was one grade 5 cardiac event which was unrelated to the study drug. 6 pts (85%) completed the planned 10-dose vaccination regimen, including one who received 14 doses during the optional maintenance phase. At the end-of-study evaluation, all had stable disease with no clinical improvement. Compared with baseline, no changes in bone marrow morphology or fibrosis grade were observed. The median mutCALR VAF remained similar (26.2% [range, 9.3–34.9%] vs 28.6% [12.7–33.6%]), as did the median platelet counts (555 × 10⁹/L [452–732] vs 521 × 10⁹/L [396–722]). One patient, however, demonstrated a sustained decline in platelet counts, reaching 27.3% at the last follow-up, accompanied by a decline in mutCALR VAF, without additional therapy.

Despite the lack of clinical responses, preliminary analyses demonstrated the immunogenicity of mutCALR vaccination. Peripheral blood mononuclear cells (PBMCs) collected before and after vaccination were stimulated with mutCALR peptide pools and T cell immunogenicity was assessed by ex vivo IFN-γ ELISPOT. No pre-existing responses were detected at baseline. Antigen-specific T cell responses were detected only after vaccination, with ≥2-fold increase in 3 of 6 pts, demonstrating that mutCALR vaccine can endogenously prime T cell responses. Importantly, no responses against the corresponding wild type CALR sequence were observed, suggesting that mutCALR vaccine did not induce cross-reactive T cells. Further functional assessment using in vitro expansion to detect low frequency antigen-specific T cells confirmed the induction of mutCALR-specific T cell responses following vaccination in 5 of 6 pts. Vaccination elicited both CD4+ and CD8+ T cells, with responses primarily mediated by CD4+ T cells. The magnitude of vaccine-induced T cell responses varied across pts, potentially reflecting the immunosuppressive effects of the chronic inflammatory milieu associated with MPNs. Supporting this notion, we observed that ex vivo PD-1 blockade could enhance vaccine-induced CD8+ T cell responses. In exploratory analyses, single-cell RNA sequencing of longitudinal samples from four patients suggested temporal remodeling of the myeloid compartment with a shift toward a less immunosuppressive transcriptional state following vaccination.

Conclusions: These findings indicate that off-the-shelf mutCALR vaccination is safe and can induce de novo CD4+ and CD8+ T cell responses in pts with MPN carrying CALR mutations. The absence of clinical activity despite vaccine immunogenicity supports further investigation of combination strategies aimed at overcoming immune suppression. Additional immune-monitoring analyses are underway to provide an in-depth characterization of tumor-immune dynamics in CALR+ MPN during mutCALR vaccination and results will be presented at the conference.
Cansu Cimen Bozkus, PhD: No relevant conflicts of interest to declare.